Skip to main content

Table 1 FDO outcomes in the three centres

From: A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure

 

Site 1 Cantonal Hospital, Aarau

Site 2 Clinique de Carouge SA

Site 3 Neurocentre Bellevue

Total

Total number of patients undergoing FDO

58

17

61

136

Patients with no FDO events (n)

57

16

57

130

Patients discharged at 6 hours (n)

57

16

59

132

Patients requiring extended observation after 6 hours (n)

1a

0

0

1

Patients requiring observation on 2nd day (n)

0

1b

2c

3

Symptomatic patients (n)

0

0

2d

2

Patients with ECG Abnormalities (n)

1a

1b

2c

4

1st degree AV Block (n)

0

0

2c

2

2nd degree AV Block Type I (Wenkebach) (n)

1a

1b

0

2

2nd degree AV Block Type II (Mobitz Type II) (n)

0

0

0

0

Symptomatic events that resolved by the end of 6 h observation (n)

0

0

2d

2

ECG events that had resolved at extended observation or follow-up examination on the 2nd day (n)

1a

1b

2c

4

  1. a2nd degree AV block, Wenkebach type: extension of observation by 1 h and repeat of ECG; AV block had resolved.
  2. b2nd degree AV block, Wenkebach type: 24 h Holter ECG as a precautionary measure; AV block had resolved and no further finding observed on Holter ECG.
  3. c1st degree AV blocks: patients were asked to return to the practice the next day for a single ECG; AV block had resolved.
  4. d1 patient with vertigo-like sensation, 1 patient with palpitations (HR in normal range 74 bpm): symptoms had resolved for both patients by the end of the 6 h observation.
  5. AV, atrioventricular; HR, heart rate; bpm, beats per minute.